^
    9d
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (clinicaltrials.gov)
    P3, N=863, Active, not recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jan 2027 --> Jun 2026
    Trial completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • paclitaxel • 5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • levoleucovorin calcium
    1m
    An open-label, multicenter Phase Ib/II clinical study on the safety, tolerability, pharmacokinetics, and efficacy of QLC5508 injection combined therapy in patients with advanced solid tumors (ChiCTR2500110587)
    P1/2, N=414, Not yet recruiting, Shanghai East Hospital; Qilu Pharmaceutical Co.
    New P1/2 trial
    |
    cisplatin • carboplatin • paclitaxel • 5-fluorouracil • oxaliplatin • Qibeian (iparomlimab/tuvonralimab) • MHB088C • levoleucovorin calcium
    3ms
    Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors (clinicaltrials.gov)
    P2, N=53, Active, not recruiting, Taiho Oncology, Inc. | Trial primary completion date: Jul 2025 --> Mar 2026
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • oxaliplatin • Lytgobi (futibatinib) • irinotecan • levoleucovorin calcium
    3ms
    KEYMAKER-U06 Substudy 06E: Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06) (clinicaltrials.gov)
    P1/2, N=228, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting | Trial completion date: Feb 2031 --> Jan 2032 | Trial primary completion date: Feb 2031 --> Jan 2032
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Keytruda (pembrolizumab) • 5-fluorouracil • oxaliplatin • ifinatamab deruxtecan (DS-7300) • levoleucovorin calcium
    3ms
    Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014) (clinicaltrials.gov)
    P3, N=863, Active, not recruiting, Merck Sharp & Dohme LLC | Trial primary completion date: Jan 2027 --> May 2025
    Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • cisplatin • paclitaxel • 5-fluorouracil • Lenvima (lenvatinib) • oxaliplatin • levoleucovorin calcium
    4ms
    BREAKWATER: A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov)
    P3, N=831, Active, not recruiting, Pfizer | Trial completion date: Dec 2026 --> Dec 2027
    Trial completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF V600E • BRAF V600
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • capecitabine • Braftovi (encorafenib) • oxaliplatin • irinotecan • leucovorin calcium • Khapzory (levoleucovorin) • levoleucovorin calcium
    4ms
    A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
    P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Jun 2031 --> Oct 2030
    Trial completion date
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
    4ms
    A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (clinicaltrials.gov)
    P3, N=477, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
    4ms
    An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P2, N=26, Recruiting, National Cancer Center Hospital East | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Keytruda (pembrolizumab) • docetaxel • 5-fluorouracil • oxaliplatin • levoleucovorin calcium
    4ms
    Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
    P3, N=269, Recruiting, Fujian Cancer Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    paclitaxel • 5-fluorouracil • Tevimbra (tislelizumab-jsgr) • oxaliplatin • leucovorin calcium • levoleucovorin calcium
    5ms
    NuTide:303: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1/2, N=19, Terminated, NuCana plc | N=91 --> 19 | Trial completion date: Dec 2025 --> May 2025 | Recruiting --> Terminated | Trial primary completion date: Dec 2025 --> May 2025; The NuTide:303 study was terminated at NuCana's discretion due to refinement of the pipeline strategy. The overall risk benefit assessment of NUC-3373 remains positive and future NUC-3373 studies are under consideration.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    MSI (Microsatellite instability)
    |
    Keytruda (pembrolizumab) • docetaxel • fosifloxuridine nafalbenamide (NUC-3373) • levoleucovorin calcium
    5ms
    LIGHTBEAM-02A: A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) (clinicaltrials.gov)
    P1/2, N=180, Recruiting, Merck Sharp & Dohme LLC | N=130 --> 180
    Enrollment change
    |
    Keytruda (pembrolizumab) • cisplatin • 5-fluorouracil • Jiataile (sacituzumab tirumotecan) • levoleucovorin calcium